ONON inventory forecast 2025 refers back to the predicted efficiency of Onconova Therapeutics, Inc. (ONON) inventory over the subsequent few years. It will be significant for buyers to contemplate inventory forecasts as they will present useful insights into the potential development and profitability of an organization.
ONON is a clinical-stage biopharmaceutical firm targeted on discovering and creating novel most cancers therapies. The corporate’s lead product candidate, rigosertib, is a small molecule that targets a number of signaling pathways concerned in most cancers development and survival. Rigosertib is at present being evaluated in a number of medical trials for the therapy of varied varieties of most cancers, together with lung most cancers, breast most cancers, and pancreatic most cancers.
